Literature DB >> 25655053

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

D M Skowronski1, C Chambers, S Sabaiduc, G De Serres, J A Dickinson, A L Winter, S J Drews, K Fonseca, H Charest, J B Gubbay, M Petric, M Krajden, T L Kwindt, C Martineau, A Eshaghi, N Bastien, Y Li.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25655053     DOI： 10.2807/1560-7917.es2015.20.4.21022

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


× No keyword cloud information.
  42 in total

1.  Whole genome sequencing identifies influenza A H3N2 transmission and offers superior resolution to classical typing methods.

Authors:  Dominik M Meinel; Susanne Heinzinger; Ute Eberle; Nikolaus Ackermann; Katharina Schönberger; Andreas Sing
Journal:  Infection       Date:  2017-10-31       Impact factor: 3.553

2.  Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in France.

Authors:  Cécile Souty; Thierry Blanchon; Isabelle Bonmarin; Daniel Lévy-Bruhl; Sylvie Behillil; Vincent Enouf; Martine Valette; Maude Bouscambert; Clément Turbelin; Lisandru Capai; Victoire Roussel; Thomas Hanslik; Alessandra Falchi
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  "Crude Vaccine Effectiveness" Is a Misleading Term in Test-negative Studies of Influenza Vaccine Effectiveness.

Authors:  Sheena G Sullivan; Benjamin J Cowling
Journal:  Epidemiology       Date:  2015-09       Impact factor: 4.822

4.  A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants.

Authors:  Vasiliy P Mishin; Tatiana Baranovich; Rebecca Garten; Anton Chesnokov; Anwar I Abd Elal; Michelle Adamczyk; Jennifer LaPlante; Kirsten St George; Alicia M Fry; John Barnes; Stephanie C Chester; Xiyan Xu; Jacqueline M Katz; David E Wentworth; Larisa V Gubareva
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

5.  Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Authors:  A F Altenburg; S E Magnusson; F Bosman; L Stertman; R D de Vries; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

Review 6.  Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Authors:  Manon M J Cox; Ruvim Izikson; Penny Post; Lisa Dunkle
Journal:  Ther Adv Vaccines       Date:  2015-07

7.  Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Stella E van Trierum; Heidi L M De Gruyter; Peter R W A van Run; Ron A M Fouchier; Kenny Roose; Xavier Saelens; Asisa Volz; Gerd Sutter; Rory D de Vries; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 8.  Adjuvanted influenza vaccines.

Authors:  John S Tregoning; Ryan F Russell; Ekaterina Kinnear
Journal:  Hum Vaccin Immunother       Date:  2018-01-25       Impact factor: 3.452

9.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

10.  Effectiveness of the 2013 and 2014 Southern Hemisphere Influenza Vaccines Against Laboratory-confirmed Influenza in Young Children Using a Test-negative Design, Bangkok, Thailand.

Authors:  Wanitchaya Kittikraisak; Piyarat Suntarattiwong; Darunee Ditsungnoen; Chonticha Klungthong; Stefan Fernandez; In-Kyu Yoon; Kim Lindblade; Fatimah S Dawood; Sonja J Olsen; Tawee Chotpitayasunondh
Journal:  Pediatr Infect Dis J       Date:  2016-10       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.